PAT CONNECT 2026: Register now!

08.12.2025

The PAT Connect Conference will take place in Badenweiler on March 10 and 11, 2026. It brings together experts in pharmaceutical process analytics from industry, science, and regulatory authorities.

Expand your network.

Program and registration

On March 12, you will have the opportunity to visit the Glatt Innovation Center in Weil-Haltingen.

The international conference expects 150 to 250 leading experts from industry, science, and government agencies to discuss the latest developments in process analytical technology (PAT). Special focus will be placed on AI applications, continuous production, and data analytics, supplemented by regulatory perspectives and practical examples from industry.

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Concept Paper on the Revision of Annex 15

11.02.2026

News

EMA: Concept Paper on the Revision of Annex 15

EMA and PIC/S have published a concept paper outlining a targeted revision of Annex 15 (Qualification and Validation).

What do Typical Manufacturing Processes for Sterile Products look like?

09.02.2026

Question of the Week

What do Typical Manufacturing Processes for Sterile Products look like?

Here's the answer:

Human Resource Management as a Key to Success

09.02.2026

LOGFILE Feature

Human Resource Management as a Key to Success

The pharmaceutical industry in Germany and other countries, too, faces considerable challenges in the area of human resource management. These problems have far-reaching implications for the competitiveness and innovative power of the industry.

EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

06.02.2026

News

EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

The EMA has published a new reflection paper outlining its current thinking on the qualification of non-mutagenic impurities (NMIs). The paper addresses recommended approaches for evaluating the safety of new or increased impurity levels, particularly when such impurities exceed the ICH Q3A/Q3B qualification thresholds and are identified after completion of non-clinical toxicology studies.

EMA: Discussions on the Revised ERA Guideline

06.02.2026

News

EMA: Discussions on the Revised ERA Guideline

During the second industry stakeholder webinar on the revised guideline on environmental risk assessment (ERA) for medicinal products for human use, the European Medicines Agency (EMA) addressed key implementation challenges observed during the first year of application.

EMA: New Q&A on Product Lifecycle Management (PLCM)

30.01.2026

News

EMA: New Q&A on Product Lifecycle Management (PLCM)

The EMA has published new Questions & Answers on the use of the Product Lifecycle Management (PLCM) document, clarifying its role within the EU variations framework for post-approval quality changes.